SNY's Rilzabrutinib Wins 4th Orphan Drug Tag for Sickle Cell Disease

The FDA granted Sanofi's (SNY) rilzabrutinib orphan drug designation for sickle cell disease (SCD), marking its fourth such designation; rilzabrutinib is also under FDA review for immune thrombocytopenia (ITP), with a decision expected by August 29, 2025. Preclinical data showed rilzabrutinib reduced vaso-occlusion and inflammation in SCD mouse models, though the candidate is yet to enter clinical trials for the SCD indication. Year-to-date, Sanofi shares have gained 2%, compared to the industry's 3.2% decline.

Analysis

Sanofi's investigational BTK inhibitor, rilzabrutinib, has secured its fourth FDA orphan drug designation, this time for Sickle Cell Disease (SCD), a rare genetic disorder affecting over 100,000 people in the U.S. This designation supports the development of medicines for rare disorders impacting fewer than 200,000 U.S. patients. Although rilzabrutinib for SCD is yet to enter clinical-stage development, preclinical studies in mouse models demonstrated reduced vaso-occlusion and inflammation. Rilzabrutinib's potential is further underscored by its ongoing FDA review for Immune Thrombocytopenia (ITP), with a decision expected by August 29, 2025; it already holds orphan drug status for ITP in the U.S., EU, and Japan, alongside a U.S. Fast Track designation. In April 2025, the FDA also granted orphan drug status to rilzabrutinib for warm autoimmune hemolytic anemia (wAIHA) and IgG4-related disease (IgG4-RD), both conditions with significant unmet medical needs and no currently approved therapies. Phase IIb data for wAIHA showed clinically meaningful outcomes, and Phase IIa data for IgG4-RD indicated reduced disease flare and glucocorticoid sparing. Rilzabrutinib, acquired through Principia Biopharma, is also in mid-stage development for other immune-mediated diseases like asthma and chronic spontaneous urticaria. Year-to-date, Sanofi's shares have gained 2%, outperforming the industry's 3.2% decline. Sanofi currently carries a Zacks Rank #2 (Buy). For broader sector context, Bayer's (BAYRY) EPS estimates for 2025 increased from $1.19 to $1.25 and for 2026 from $1.28 to $1.31 in the past 60 days, with its stock up 45.9% YTD. Lexicon's (LXRX) loss per share estimates narrowed for 2025 from 37 to 32 cents and for 2026 from 35 to 31 cents, though its shares are down 14.4% YTD. Amarin's (AMRN) loss per share estimates for 2025 narrowed from $5.00 to $2.78 and for 2026 from $3.87 to $2.04, with its stock gaining 23.2% YTD.

Key Decisions for Investors

• The accumulation of multiple orphan drug designations for rilzabrutinib, including the latest for Sickle Cell Disease, signals a strengthening pipeline with potential in several underserved rare disease markets, possibly reducing future development timelines and costs for these indications.
• Investors should mark August 29, 2025, on their calendars for the FDA's decision on rilzabrutinib for Immune Thrombocytopenia, which represents a significant near-term catalyst that could materially impact Sanofi's valuation.
• Monitor Sanofi's clinical trial progress for rilzabrutinib in SCD, wAIHA, and IgG4-RD, as positive data readouts from these programs could further validate the drug's broad applicability and contribute to sustained stock outperformance, especially given the current positive momentum versus the industry.